CSL Bullish on Immunoglobulins, Bearish On Plasma Pricing
This article was originally published in PharmAsia News
Executive Summary
TOKYO - CSL closed its 2010 fiscal year with a mixed bag of results. From gains in its plasma portfolio to disappointments in Gardasil and influenza vaccines, the Melbourne, Australia-based company's 2011 outlook is a combination of caveats and prospects